Investor Relations

About Vivani

Operating under our Biopharm Division and Neuromodulation Division, Vivani develops, manufactures, and markets therapies that target chronic conditions with high unmet medical needs. 

Our Biopharm Division develops novel, miniature drug implants by leveraging our proprietary NanoPortal™ implant technology for delivering medication steadily over extended periods of time. Our differentiated, drug implant candidates have the potential to ensure patients consistently receive the right dose while potentially avoiding safety concerns that may be associated with fluctuating delivery. 

Our Neuromodulation Division, recently organized as Cortigent, Inc., seeks to identify and assess strategic options for advancing visual prosthesis candidates. Our primary focus is developing Orion II – a Visual Cortical Prosthesis System created to bring artificial vision to individuals who are blind due to a wide range of causes.

Latest Presentation

2023 Investor Presentation

Latest Financial Results

Q1 2023

Quarter Ended March 31, 2023

Latest Annual Filing

For Fiscal Year Ending December 31, 2022

Stock Snapshot

IR Contacts


Vivani Medical, Inc.
5858 Horton Street #280
Emeryville, CA 94608
United States
T: 415-506-8462

Investor Relations

Brigid Makes
Chief Financial Officer
T: 415-506-8462

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436